geha glp-1 coverage glp 1 Drugs: 2025 Pulse Survey (U.S.) The evolving landscape of anti-obesity
Description
doi: 10.1038/s41591-023-02669-x
Read more on MIMS To view or add a comment, sign in About ATR-04, an investigational live biotherapeutic for EGFR inhibitor ("EGFRi") associated rash
When to Seek Help Some degree of nausea, bloating, or fatigue is expected in the early stages of treatment and usually improves within a few weeks
Hence, there is a continuous need for drugs that are innovative and efficacious like GLP-1 analogues, which have shown superior clinical outcomes and cardiovascular benefits as compared to traditional antidiabetic agents
Graham et al., 2020
